Increased @entity2690 requirements during exercise at very high altitude in type 1 XXXX .

@entity6 @entity2690 @entity2412 @entity5754 @entity413
OBJECTIVE: Safe, very high altitude trekking in subjects with type 1 @entity6 requires understanding of @entity413 regulation at high altitude. We investigated @entity2690 requirements, energy expenditure, and @entity413 levels at very high altitude in relation to @entity5754 ( @entity5754 ) symptoms in individuals with type 1 @entity6 . RESEARCH DESIGN AND METHODS: Eight individuals with @entity2412 part in a 14-day expedition to Mount Meru (4,562 m) and Mount Kilimanjaro (5,895 m) in Tanzania. Daily @entity2690 doses, @entity413 levels, energy expenditure, and @entity5754 symptoms were determined. Also, energy expenditure and @entity5754 symptoms were compared with a healthy control group. RESULTS: We found a positive relation between @entity5754 symptoms and @entity2690 requirements (r = 0.78; P = 0.041) and @entity5754 symptoms and @entity413 levels (r = 0.86; P = 0.014) for Mount Kilimanjaro. Compared with sea level, @entity2690 doses tended to decrease by 14.2% (19.7) (median [interquartile range]) (P = 0.41), whereas @entity413 levels remained stable up to 5,000 m altitude. However, at altitudes >5,000 m, @entity2690 dose was unchanged (36.8    17 vs. 37.6    19.1 international units [mean    SD] P = 0.75), but @entity413 levels (7.5    0.6 vs. 9.5    0.8 mmol/L [mean    SD] P = 0.067) and @entity5754 scores (1.3    1.6 vs. 4.4    4 points [mean    SD] P = 0.091) tended to increase. Energy expenditure and @entity5754 symptoms were comparable in both groups (P = 0.84). CONCLUSIONS: Our data indicate that in complication-free individuals with type 1 @entity6 , @entity2690 requirements tend to increase during altitudes above 5,000 m despite high energy expenditure. This change may be explained, at least partly, by @entity5754 .
